Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial
Journal
Liver cancer
Journal Volume
12
Journal Issue
1
Pages
72
Date Issued
2023-02
Author(s)
Ren, Zhenggang
Ducreux, Michel
Abou-Alfa, Ghassan K
Merle, Philippe
Fang, Weijia
Edeline, Julien
Li, Zhiwei
Wu, Lihua
Assenat, Eric
Hu, Sheng
Rimassa, Lorenza
Zhang, Tao
Blanc, Jean-Frédéric
Pan, Hongming
Ross, Paul
Yen, Chia-Jui
Tran, Albert
Shao, Guoliang
Bouattour, Mohamed
Chen, Yajin
Meyer, Tim
Hou, Jinlin
Tougeron, David
Bai, Yuxian
Hou, Ming-Mo
Meng, Zhiqiang
Wu, John
Li, Vincent
Chica-Duque, Sandra
Abstract
Tislelizumab (anti-programmed cell death protein 1 antibody) showed preliminary antitumor activity and tolerability in patients with advanced solid tumors, including hepatocellular carcinoma (HCC). This study aimed to assess the efficacy and safety of tislelizumab in patients with previously treated advanced HCC.
Subjects
Hepatocellular carcinoma; Immunotherapy; Pretreated patient population; Tislelizumab
SDGs
Publisher
KARGER
Type
journal article